Aradigm Corporation (ARDM) - Financial and Strategic Analysis Review
Reference Code: GDME1294FSA Publication Date: AUG 2010
3929 Point Eden Way Phone +1 510 2659000 Revenue 4.9 (million USD)
Hayward, CA Fax +1 510 2650277 Net Profit -13.77 (million USD)
94545 Website www.aradigm.com Employees 15
United States Exchange ARDM [Over The Counter] Industry Medical Equipment
Company Overview
Aradigm Corporation (Aradigm) is a specialty pharmaceutical company engaged in the development and commercialization of
drugs delivered by inhalation for treating severe respiratory diseases by pulmonologists. It has developed pulmonary drug
delivery system, AERx Essence and AERx Strip Technology for the delivery of drugs to the target. The company's current
pipeline comprises of products used for treating cystic fibrosis, inhalation anthrax and bronchiectasis. Its research and
development activity consisted of collaborative and contracted research on the pipeline products and existing products in the
market.
Key Executives SWOT Analysis
Name Title Aradigm Corporation, SWOT Analysis
Igor Gonda, Ph.D. Chief Executive Officer Strengths Weaknesses
Virgil D. Thompson Chairman
Dependence on Contract
Frank H. Barker Director Intellectual Property Rights Manufacturers
Dr. John M. Siebert Director
Strong Liquidity Position Limited Operating Margin
Nancy Pecota Chief Financial Officer
Source: Annual Report, Company Website, Primary and Secondary Research
GlobalData
Opportunities Threats
Share Data
Aradigm Corporation Rising Healthcare Uncertain R&D Outcomes
Share Price (USD) as on 25-Aug-2010 0.20 Expenditure in the US
-0.15 Competitive Market
EPS (USD)
Pipeline Products
Market Cap (million USD) 22
Enterprise Value (million USD) 21
Shares Outstanding (million) 138 Source: Annual Report, Company Website, Primary and Secondary Research
Source: Annual Report, Company Website, Primary and Secondary Research GlobalData
GlobalData
Financial Performance